11/19
02:49 pm
bbio
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market [Yahoo! Finance]
Low
Report
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market [Yahoo! Finance]
11/19
06:25 am
bbio
The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically [Yahoo! Finance]
Low
Report
The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically [Yahoo! Finance]
11/18
11:28 am
bbio
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months [Yahoo! Finance]
Medium
Report
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months [Yahoo! Finance]
11/18
11:15 am
bbio
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
Low
Report
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
11/18
05:31 am
bbio
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia [Yahoo! Finance]
Medium
Report
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia [Yahoo! Finance]
11/18
05:30 am
bbio
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
Medium
Report
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
11/15
12:19 pm
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at Scotiabank from $44.00 to $45.00. They now have a "sector outperform" rating on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at Scotiabank from $44.00 to $45.00. They now have a "sector outperform" rating on the stock.
11/14
05:32 am
bbio
BridgeBio Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
Medium
Report
BridgeBio Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
11/12
09:54 am
bbio
BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Medium
Report
BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
11/12
07:30 am
bbio
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update
Medium
Report
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update
11/5
07:30 am
bbio
BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management
Low
Report
BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management
10/25
08:37 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $43.00 price target on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $43.00 price target on the stock.
10/24
07:30 am
bbio
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024
Low
Report
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024
10/23
10:04 am
bbio
Investors in BridgeBio Pharma (NASDAQ:BBIO) have unfortunately lost 49% over the last three years [Yahoo! Finance]
Low
Report
Investors in BridgeBio Pharma (NASDAQ:BBIO) have unfortunately lost 49% over the last three years [Yahoo! Finance]
10/17
11:36 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target lowered by analysts at Leerink Partners from $47.00 to $46.00. They now have an "outperform" rating on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target lowered by analysts at Leerink Partners from $47.00 to $46.00. They now have an "outperform" rating on the stock.
10/16
08:44 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
10/4
05:42 am
bbio
3 Top Stocks That Could Still Rocket Higher in 2024 [Yahoo! Finance]
Low
Report
3 Top Stocks That Could Still Rocket Higher in 2024 [Yahoo! Finance]
10/3
08:17 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Oppenheimer Holdings Inc.. They set a "market perform" rating on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Oppenheimer Holdings Inc.. They set a "market perform" rating on the stock.
10/3
07:30 am
bbio
BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
Low
Report
BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
9/30
01:29 pm
bbio
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease [Yahoo! Finance]
Low
Report
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease [Yahoo! Finance]
9/30
08:01 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $43.00 price target on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $43.00 price target on the stock.
9/30
07:30 am
bbio
BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
Low
Report
BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
9/27
06:09 pm
bbio
BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events [Yahoo! Finance]
Low
Report
BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events [Yahoo! Finance]
9/27
06:00 pm
bbio
BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events
Low
Report
BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events
9/17
07:30 am
bbio
BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
Low
Report
BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA